Delaware
|
1-38519
|
82-1436829
|
(State or other jurisdiction
|
(Commission File Number)
|
(IRS Employer
|
of incorporation)
|
|
Identification No.)
|
Title of each class
|
Trading Symbol
|
Name of exchange on which registered
|
Common Stock, par value $0.0001 per share
|
AGE
|
NYSE American
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Exhibit Number
|
Description |
99.1 | Press release dated August 14, 2020 |
|
AGEX THERAPEUTICS, INC.
|
|
|
|
|
|
|
Date: August 14, 2020
|
By:
|
/s/ Andrea Park
|
|
|
|
Chief Financial Officer
|
|